Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Background and objective Immunotherapy represented by immune checkpoint inhibitors (ICIs) has been widely used in the treatment of lung cancer. There are controversies in clinical practice for patients with advanced non-small cell lung cancer (NSCLC) and high programmed cell death-ligand 1 (PD-L1) e...

Full description

Bibliographic Details
Main Authors: Haoyang LI, Na QIN, Mengjun YU, Li MA, Yuhua WU, Hui ZHANG, Xinyong ZHANG, Xi LI, Jinghui WANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021-03-01
Series:Chinese Journal of Lung Cancer
Subjects:
immune checkpoint blockade
lung neoplasms
programmed cell death-ligand 1
monotherapy
combination chemotherapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2021.103.02

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2021.103.02

Similar Items